- Home
- DTM vs EXEL Comparison
DTM vs EXEL Comparison
Compare DTM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTM
- EXEL
- Stock Information
- Founded
- DTM 2021
- EXEL 1994
- Country
- DTM United States
- EXEL United States
- Employees
- DTM N/A
- EXEL N/A
- Industry
- DTM Oil & Gas Production
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTM Utilities
- EXEL Health Care
- Exchange
- DTM Nasdaq
- EXEL Nasdaq
- Market Cap
- DTM 10.1B
- EXEL 10.0B
- IPO Year
- DTM N/A
- EXEL 2000
- Fundamental
- Price
- DTM $98.70
- EXEL $34.69
- Analyst Decision
- DTM Hold
- EXEL Buy
- Analyst Count
- DTM 10
- EXEL 17
- Target Price
- DTM $85.44
- EXEL $32.18
- AVG Volume (30 Days)
- DTM 1.0M
- EXEL 1.7M
- Earning Date
- DTM 10-29-2024
- EXEL 02-04-2025
- Dividend Yield
- DTM 2.99%
- EXEL N/A
- EPS Growth
- DTM 15.08
- EXEL 441.02
- EPS
- DTM 4.11
- EXEL 1.55
- Revenue
- DTM $976,000,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- DTM $7.56
- EXEL $20.59
- Revenue Next Year
- DTM $16.97
- EXEL $1.50
- P/E Ratio
- DTM $23.89
- EXEL $22.41
- Revenue Growth
- DTM 5.97
- EXEL 17.31
- 52 Week Low
- DTM $51.17
- EXEL $19.20
- 52 Week High
- DTM $109.85
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- DTM 46.89
- EXEL 49.52
- Support Level
- DTM $98.09
- EXEL $34.58
- Resistance Level
- DTM $102.69
- EXEL $36.22
- Average True Range (ATR)
- DTM 2.51
- EXEL 0.77
- MACD
- DTM -1.10
- EXEL -0.29
- Stochastic Oscillator
- DTM 20.99
- EXEL 14.61
About DTM DT Midstream Inc.
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.